Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 3

A case of entecavir-associated bullous fixed drug eruption and a review of literature

Pages
299–302
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, we performed a reviewof literature to compile previously reported entecavir-associated drug reactions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the samesite(s), generally observed following every intake of a causative drug.
📊
Key Findings & Data:Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE.
💡
Conclusion & Impact:Furthermore, we performed a reviewof literature to compile previously reported entecavir-associated drug reactions.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the samesite(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC) is considered toplay a role in FDE etiology. Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE. Bullous FDE, on the otherhand, is a relatively rare form of FDE. Hepatitis B is a significant worldwide health problem, and entecavir is a common nucleoside(deoxyguanosine) analog used for treating hepatitis B; however, it has various side effects, such as lactic acidosis, myalgia, azotemia,hypophosphatemia, headache, diarrhea, pancreatitis, and neuropathy, and, in rare cases, cutaneous drug eruption. Our aim is to presenta case of entecavir-associated bullous drug reaction, which has not been reported in the literature. Furthermore, we performed a reviewof literature to compile previously reported entecavir-associated drug reactions.

🔖

Cite This Article

TEMİZ, S. A., ÖZER, İ., ATASEVEN, A., FINDIK, S. (2019). A case of entecavir-associated bullous fixed drug eruption and a review of literature. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 3, 299–302. https://ajindex.com/articles/409272

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Flowers H, Brodell R, Brents M, et al. Fixed drug eruptions: presentation, diagnosis, and management. South Med J 2014; 107: 724-7. [CrossRef] Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol 2009; 9: 316-21. [CrossRef] Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016; 43: 134-44. [CrossRef] Marzano A, Marengo A, Marietti M, et all. Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis 2011; 43: 1027-8. [CrossRef] Yamada S, Sawada Y, Nakamura M. Maculopapular-type drug eruption caused by entecavir. Eur J Dermatol 2011; 21: 635-6.
  2. Genest G, Thomson DM. Fixed drug eruption to quinine: a case report and review of the literature. J Allergy Clin Immunol 2014; 2: 469. [CrossRef] Jain SP, Jain PA. Bullous Fixed Drug Eruption to Ciprofloxacin: A Case Report. J Clin Diagn Res 2013; 7: 744-45. [CrossRef] Barbaud A, Reichert-Penetrat S, Trechot P, et al. The use of testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139: 49-58. [CrossRef] Ozkaya-Bayazit E. Topical provocation in fixed drug eruption due to metamizol and naproxen. Clin Exp Dermatol 2004; 29: 419-22. [CrossRef] Ozkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges 2008; 6: 181-8. [CrossRef] Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am J Clin Dermatol 2003; 4: 407-28. [CrossRef] Sugiura K, Sugiura M, Takashi T, Naoki H, Itoh A. Immediate allergy, drug-induced eruption, by entecavir. J Eur Acad Dermatol Venereol 2009; 23: 487-9. [CrossRef] Yoon J, Park D, Kim C. A granulomatous drug eruption induced by entecavir. Ann Dermatol 2013; 25: 493-5. [CrossRef] Taura M, Asai J, Cho Z, Wada M, Katoh N. Drug eruption due to entecavir: A case report and mini-review. Allergol Int 2016; 65: 334- 5. [CrossRef] Kim JT, Jeong HW, Choi KH, et al. Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B. World J Gastroenterol 2014; 20: 15931. [CrossRef] Rivkin A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today 2007; 43: 201-20. [CrossRef] Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a gene